8 results about "CD23" patented technology

GITRL+ IgDlow / − B cells as well as methods of making and using said cells are described herein. Also described are methods for treating an autoimmune disease or an inflammatory condition in a subject in need thereof of using said B cells. The B cells may be GITRL+ IgDlowCCR7+ CXCR5+ B cells or GITRL+ IgDlow CCR7+ CXCR5+ CD23+ CD24+ B cells.

The invention relates to the technical field of immunology and biomedicine, in particular to application of CD23 as a target spot to preparation of a medicine for treating IL-17 mediated diseases. By enhancing the expression or function of CD23, an IL-7R alpha-mediated mTORC2-AKT signal channel is activated, the expression of Bcl-2 is promoted, and the apoptosis of NKT17 cells is inhibited, so that the steady state and function of the NKT17 cells are maintained. Experimental results show that the deletion of CD23 causes the reduction of NKT17 cells, the expression of p-AKT (Ser473) and Bcl-2 is reduced, and the signal activity can be recovered by the supplementation of exogenous IL-7. The dependency of the signal path is further verified by using an mTORC2 inhibitor. An airway hyperreactivity model experiment shows that the lung airway hyperreactivity of a CD23-deficient mouse can be reduced, the IL-17 level is reduced, and the inflammatory response is relieved.

A staining kit is provided, including a first pattern including antibodies against T cell, B cell, NK cell, monocyte, regulatory cell, CD8, CD45, and CTLA4; a second pattern including antibodies against T cell, B cell, NK cell, monocyte, regulatory cell, dendritic cell, and CD45; a third pattern including antibodies against T cell, B cell, NK cell, monocyte, CD8, CD45, CD45RA, CD62L, CD197, CX3CR1 and TCRαβ; and a fourth pattern including antibodies against B cell, CD23, CD38, CD40, CD45 and IgM, wherein the antibodies of each pattern are labeled with fluorescent dyes. A method of identifying characterized immune cell subsets of a disease and a method of predicting the likelihood of NPC in a subject in the need thereof using the staining kit are also provided.

The present invention relates to the field of medical diagnosis. In particular, the present invention relates to methods and kits for determining the therapeutic efficacy of allergen immunotherapy and for measuring or detecting biomarkers in a subject undergoing allergen immunotherapy. For example, the present invention provides a method for determining the efficacy of allergen immunotherapy in a subject, the method comprising the steps of providing a first sample obtained from the subject prior to receiving allergen immunotherapy, providing a second sample obtained from a subject who has received or is receiving allergen immunotherapy, wherein the first and second samples comprise B cells, and determining the level or amount of one or more biomarkers in the B cells of the first and second samples, preferably allergen-specific B cells, wherein the biomarker is selected from the group consisting of IgE, CD29, CD69, IL13Rα, CD99, IgD, CXCR4, FCRL3, FCRL2, FCRL5, SIGLEC10, CD1c, CD23, and IL4Rα, and an increase in the level or amount of one or more biomarkers selected from IgE, CD29, IL13Rα, CD99, FCRL3, FCRL2, SIGLEC10, CD1c, CD23, and IL4Rα in the B cells of the second sample as compared to the first sample indicates the efficacy of allergen immunotherapy in the subject, and / or a decrease in the level or amount of one or more biomarkers selected from CD69, IgD, CXCR4, FCRL3, FCRL2, FCRL5, CD1c, CD23, and IL4Rα in the B cells of the second sample as compared to the first sample indicates the efficacy of allergen immunotherapy in the subject.

The present invention relates to the field of medical diagnostics. In particular, it relates to methods and kits for determining treatment efficacy of allergen immunotherapy, and for measuring or detecting biomarkers in a subject undergoing allergen immunotherapy. For example, the invention provides a method of determining efficacy of an allergen immunotherapy in a subject, the method comprising: providing a first sample obtained from a subject before receiving allergen immunotherapy; providing a second sample obtained from the subject who has received, or who is receiving, allergen immunotherapy; wherein the first and second samples comprise B-cells; and determining the level or amount of one or more biomarkers in B-cells, preferably allergen-specific B-cells, in the first and second samples, wherein the biomarkers are selected from the group consisting of IgE, CD29, CD69, IL13Rα, CD99, IgD, CXCR4, FCRL3, FCRL2, FCRL5, SIGLEC10, CDIc, CD23, and IL4Rα; wherein an increase in the level or amount of one or more biomarkers selected from IgE, CD29, IL13Rα, CD99, FCRL3, FCRL2, SIGLEC10, CD1c, CD23, and IL4Rα in B-cells in the second sample compared to the first sample indicates efficacy of an allergen immunotherapy in a subject, and / or wherein a decrease in the level or amount of one or more biomarkers selected from CD69, IgD, CXCR4, FCRL3, FCRL2, FCRL5, CD1c, CD23, IL4Rα in B-cells in the second sample compared to the first sample indicates efficacy of an allergen immunotherapy in a subject.

This application relates to a method, system, device, and medium for predicting colorectal cancer recurrence based on pathological features. The method includes: screening colorectal cancer subjects; obtaining paraffin-embedded tumor tissue blocks, clinicopathological data, and long-term follow-up data containing recurrence records; obtaining HE-stained sections and CD3 / CD20 / CD21 / CD23 immunohistochemical sections; identifying the tertiary lymphoid structures of the tumor and pre-defined boundary regions; extracting their density and maturity characteristics and traditional pathological features; integrating them into a standardized feature set; correlating the feature set with follow-up data; and screening for independent influencing factors of recurrence using univariate / multivariate logistic regression; constructing and validating a nomogram prediction model; and using it for recurrence risk assessment in newly postoperative patients. This method, by integrating tertiary lymphoid structure features with traditional pathological features and constructing a nomogram prediction model based on multivariate analysis, improves the accuracy and reliability of colorectal cancer recurrence risk prediction, providing more precise prognostic assessment and personalized treatment decision support for clinicians.

The present invention relates to biomarkers for detecting atypical depression, and provides an application method for detecting differential expression levels of CD23 and PTX3 proteins as plasma biomarkers for atypical depression. The method of the present invention is used for subtype classification diagnosis of atypical depression for non-diagnostic purposes, thereby improving the sensitivity and specificity of atypical depression screening.

Immunotherapeutic compositions comprising CD23-binding moieties and uses of the same for treatment of conditions such as autoimmunity and cancer are provided. Bispecific molecules are provided.